A Research on: Formulation and Evaluation of Sustained Release matrix Tablets

The study focused on developing a sustained release matrix tablet of Mosapride Citrate to achieve prolonged therapeutic effects, reduce side effects, and improve patient compliance by minimizing dosing frequency. Mosapride Citrate, with a half-life of 2-3 hours, was used as a model drug. Matrix tablets were prepared using different viscosity grades of Eudragit through direct compression and evaluated. Results indicated that polymer matrices alone were insufficient for 8-hour sustained release, whereas a combination of Eudragit RS 100, Eudragit RL 100, and Eudragit E 100 provided effective sustained release, primarily through diffusion. The study also aimed to identify and rectify manufacturing defects. Mosapride Citrate tablets displayed good dissolution and tableting behavior. Preformulation studies evaluated physical properties like bulk and tapped density, angle of repose, compressibility, and Housner’s ratio. Tablet formulations underwent evaluations for thickness, hardness, friability, weight variation, assay, dissolution, and stability, with optimized formulations compared to marketed samples.